Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, New York University Langone Medical Center, New York, NY.
Department of Pathology, New York University Langone Medical Center, New York, NY.
Am J Obstet Gynecol. 2016 Mar;214(3):321-7. doi: 10.1016/j.ajog.2015.12.061. Epub 2016 Jan 6.
Stem cells are undifferentiated cells with the capacity for differentiation. Amniotic fluid cells have emerged only recently as a possible source of stem cells for clinical purposes. There are no ethical or sampling constraints for the use of amniocentesis as a standard clinical procedure for obtaining an abundant supply of amniotic fluid cells. Amniotic fluid cells of human origin proliferate rapidly and are multipotent with the potential for expansion in vitro to multiple cell lines. Tissue engineering technologies that use amniotic fluid cells are being explored. Amniotic fluid cells may be of clinical benefit for fetal therapies, degenerative disease, and regenerative medicine applications. We present a comprehensive review of the evolution of human amniotic fluid cells as a possible modality for therapeutic use.
干细胞是具有分化能力的未分化细胞。羊水细胞最近才作为一种用于临床目的的干细胞潜在来源出现。羊水细胞取材是一种标准的临床程序,用于获得大量羊水细胞,因此不存在伦理或采样限制。来源于人羊水的细胞增殖迅速,具有多能性,并且有在体外扩增为多种细胞系的潜能。正在探索使用羊水细胞的组织工程技术。羊水细胞可能对胎儿治疗、退行性疾病和再生医学应用具有临床益处。我们全面回顾了人羊水细胞作为一种治疗用途的可能方式的发展历程。